Greenphire, a provider of payment technologies for the clinical trials industry, has launched a strategic partnership with Ernst & Young (E&Y) to combine Greenphire’s eClinicalGPS technology with the global intellectual property and expertise of E&Y’s advisory practice for clients in the pharmaceutical industries.

Greenphire’s clients will have access to specialists within E&Y’s global consulting and advisory practice, which focuses on global HCP transparency regulatory compliance (the Sunshine Act). E&Y’s advisory practice will assist Greenphire’s clients in complying with more than 75 transparency regulations globally.

Also, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a web-based SAAS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all pharmaceutical operations.

“Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant,” said Sam Whitaker, co-founder and CEO of Greenphire.

“The deep technical knowledge and grounded relationships formed as a result of our long-standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight,” said Martin Holyoake, partner at E&Y.